Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akari Therapeutics PLC (ADR) | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 152,672,000 | 152,672,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Milton H. Werner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 5,315,056 | 5,315,056 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Milton H. Werner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 4,059,744 | 4,059,744 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Milton H. Werner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 2,207,671 | 2,207,671 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Abizer Gaslightwala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 1,720,000 | 71,720,000 (4%) | 0% | 0.0 | 1,032 | Ordinary Shares, par value $0.0001 per share |
| Kopin Corp | Michael Andrew Murray | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 591,366 | 591,366 | - | - | Common Stock (right to buy) | |
| Nkarta Inc | Paul J. Hastings | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 565,500 | 565,500 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Garth Lees-Rolfe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 470,861 | 470,861 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Garth Lees-Rolfe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 432,853 | 432,853 | - | - | Stock Option (Right to Buy) | |
| Kopin Corp | Michael Andrew Murray | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 408,634 | 2,667,608 (3%) | 0% | 0 | Common Stock | |
| Tscan Therapeutics Inc | Chrystal U. Louis | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 390,000 | 390,000 | - | - | Stock Option (Right to Buy) | |
| PENN Entertainment Inc | Jay A. Snowden | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 372,269 | 372,269 | - | - | Stock Options (Right to Buy) | |
| Inhibikase Therapeutics Inc | Dennis N. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 344,452 | 344,452 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 344,452 | 344,452 | - | - | Stock Option (Right to Buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 338,000 | 338,000 | - | - | Employee Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Dennis N. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 316,647 | 316,647 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 316,647 | 316,647 | - | - | Stock Option (Right to Buy) | |
| HF Foods Grp Inc | Xi Lin | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 310,559 | 310,559 | - | - | Performance Stock Units | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 305,500 | 305,500 | - | - | Stock Option (right to buy) | |
| ATI Inc | Robert S. Wetherbee | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 286,824 | 719,404 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | |
| Tscan Therapeutics Inc | Jason A. Amello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| EchoStar Corp (Class A) | Hamid Akhavan | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 263,158 | 263,158 | - | - | Restricted Stock Units | |
| Radnet Inc | Howard G. Berger | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 03 Jan 2025 | 250,000 | 40,236 (0%) | 0% | 0 | Common Stock | |
| PENN Entertainment Inc | Jay A. Snowden | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 246,881 | 1,099,926 (0%) | 0% | 0 | Common Stock | |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 236,327 | 599,137 | - | - | Class A Common Stock | |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Jan 2025 | 236,327 | 8,348,600 | - | - | Class C Common Stock | |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 22.03 per share. | 03 Jan 2025 | 236,327 | 362,810 | - | 22.0 | 5,206,402 | Class A Common Stock |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 236,327 | 9,463,559 | - | - | Common Units | |
| Copart | Daniel J. Englander | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 235,480 | 0 | - | - | Stock Option | |
| Copart | Daniel J. Englander | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.91 per share. | 03 Jan 2025 | 235,480 | 235,480 (0%) | 0% | 4.9 | 1,156,207 | Common Stock |
| Copart | Daniel J. Englander | Director | Sale of securities on an exchange or to another person at price $ 56.84 per share. | 03 Jan 2025 | 235,480 | 0 (0%) | 0% | 56.8 | 13,384,683 | Common Stock |
| Inhibikase Therapeutics Inc | Garth Lees-Rolfe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 235,383 | 235,383 | - | - | Stock Option (Right to Buy) | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 230,861 | 3,277,094 (6%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 230,861 | 0 | - | - | Performance Restricted Stock Units | |
| Robinhood Markets Inc (Class A) | Baiju Bhatt | Director | 03 Jan 2025 | 228,645 | 57,442,112 | - | - | Class B Common Stock | ||
| Robinhood Markets Inc (Class A) | Baiju Bhatt | Director | Sale of securities on an exchange or to another person at price $ 40.37 per share. | 03 Jan 2025 | 228,645 | 0 | - | 40.4 | 9,229,736 | Class A Common Stock |
| Robinhood Markets Inc (Class A) | Baiju Bhatt | Director | 03 Jan 2025 | 228,645 | 228,645 | - | - | Class A Common Stock | ||
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 225,400 | 680,107 | - | 0 | Common Stock | |
| Finnovate Acq Corp (Class A) | Wang Chiu Wong | Director, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 03 Jan 2025 | 211,153 | 211,153 | - | 0 | Class A Ordinary Share, par value $0.0001 per share | |
| Akari Therapeutics PLC (ADR) | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 208,000 | 5,249,511,500 (344%) | 0% | 0.0 | 125 | Ordinary Shares, par value $0.0001 per share |
| Frontier Grp Holdings Inc | Barry L. Biffle | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 200,000 | 964,580 | - | - | Stock Option (Right to Buy) | |
| Frontier Grp Holdings Inc | Barry L. Biffle | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.92 per share. | 03 Jan 2025 | 200,000 | 984,817 | - | 3.9 | 783,680 | Common Stock |
| Frontier Grp Holdings Inc | Barry L. Biffle | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.92 per share. | 03 Jan 2025 | 200,000 | 1,184,817 | - | 3.9 | 783,680 | Common Stock |
| Frontier Grp Holdings Inc | Barry L. Biffle | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 200,000 | 1,164,580 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 195,000 | 228,334 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Owen E. Kratz | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 192,308 | 0 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Owen E. Kratz | Director, PRESIDENT & CEO | Sale or transfer of securities back to the company at price $ 9.52 per share. | 03 Jan 2025 | 192,308 | 7,171,860 (4%) | 0% | 9.5 | 1,830,772 | Common Stock |
| Helix Energy Soln Grp Inc | Owen E. Kratz | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 192,308 | 7,364,168 (4%) | 0% | - | Common Stock | |
| CNX Resources Corp | Hayley F. Scott | Chief Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 191,667 | 191,667 | - | - | Performance Share Units | |
| CNX Resources Corp | Timothy Scott Bedard | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 191,667 | 191,667 | - | - | Performance Share Units | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 42.68 per share. | 03 Jan 2025 | 175,490 | 2,385,570 (3%) | 0% | 42.7 | 7,490,580 | Common Stock, par value $0.00001 per share |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Dennis N. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 172,191 | 172,191 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 172,191 | 172,191 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 163,333 | 2,561,060 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Chewy Inc (Class A) | Sumit Singh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.62 per share. | 03 Jan 2025 | 163,022 | 735,200 (1%) | 0% | 35.6 | 5,806,518 | Class A Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 162,540 | 162,540 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Alexander O. Schuth | COFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 162,540 | 162,540 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 162,540 | 162,540 | - | - | Stock Option (right to buy) | |
| Coherus Biosciences Inc | Bryan J. McMichael | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Frontier Grp Holdings Inc | Barry L. Biffle | Director, CEO | Sale of securities on an exchange or to another person at price $ 7.88 per share. | 03 Jan 2025 | 160,000 | 1,024,817 | - | 7.9 | 1,260,800 | Common Stock |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 151,170 | 3,105,719 (5%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 151,170 | 0 | - | - | Performance Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 150,000 | 150,000 | - | - | Restricted Stock Units | |
| Kopin Corp | Paul Baker | COO Strategic Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 146,350 | 479,530 (0%) | 0% | 0 | Common Stock | |
| Kopin Corp | Richard A. Sneider | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 136,600 | 644,741 (0%) | 0% | 0 | Common Stock | |
| Nkarta Inc | Nadir Mahmood | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 123,500 | 123,500 | - | - | Stock Option (right to buy) | |
| ATI Inc | Kimberly A. Fields | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 118,314 | 327,785 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | |
| Nkarta Inc | David R. Shook | See Remarks | 03 Jan 2025 | 117,500 | 117,500 | - | - | Stock Option (right to buy) | ||
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | |
| ATI Inc | Robert S. Wetherbee | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.63 per share. | 03 Jan 2025 | 112,866 | 606,538 (0%) | 0% | 56.6 | 6,391,602 | Common Stock, par value $0.10 per share |
| Eton Pharma Inc | Sean E. Brynjelsen | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 107,469 | 107,469 | - | - | Employee Stock Option (Right to Buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 107,350 | 107,350 | - | - | Restricted Stock Unit | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 106,723 | 0 | - | - | Restricted Share Units | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 106,723 | 492,275 (0%) | 0% | - | Common Shares | |
| Nerdwallet Inc (Class A) | Samuel Yount | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.46 per share. | 03 Jan 2025 | 106,278 | 401,751 | - | 13.5 | 1,430,502 | Class A Common Stock |
| Crown Holdings Inc | Timothy J. Donahue | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 105,157 | 544,365 (0%) | 0% | 0 | Common | |
| Nkarta Inc | Alicia J. Hager | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Nkarta Inc | Ralph Brandenberger | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Nkarta Inc | Alyssa Levin | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| PENN Entertainment Inc | Todd George | EVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 100,904 | 100,904 | - | - | Stock Options (Right to Buy) | |
| Acumen Pharma Inc | Derek M. Meisner | Chief Legal Officer & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 100,300 | 100,300 | - | - | Employee Stock Option (right to buy) | |
| Acumen Pharma Inc | Eric Siemers | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 100,300 | 100,300 | - | - | Employee Stock Option (right to buy) | |
| Robinhood Markets Inc (Class A) | Daniel M Gallagher | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 40.45 per share. | 03 Jan 2025 | 100,000 | 731,642 | - | 40.5 | 4,045,320 | Class A Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 97,200 | 97,200 | - | - | Stock Option (right to buy) | |
| ATI Inc | Donald P. Newman | EVP and CFO | 03 Jan 2025 | 94,650 | 286,356 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | ||
| Nkarta Inc | Paul J. Hastings | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 94,500 | 337,237 | - | 0 | Common Stock | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 92,800 | 2,397,727 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.74 per share. | 03 Jan 2025 | 90,965 | 3,186,129 (5%) | 0% | 55.7 | 5,070,389 | Common Stock |
| Copart | Daniel J. Englander | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 84,520 | 235,480 | - | - | Stock Option | |
| Copart | Daniel J. Englander | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.91 per share. | 03 Jan 2025 | 84,520 | 84,520 (0%) | 0% | 4.9 | 414,993 | Common Stock |
| Copart | Daniel J. Englander | Director | Sale of securities on an exchange or to another person at price $ 57.10 per share. | 03 Jan 2025 | 84,520 | 0 (0%) | 0% | 57.1 | 4,826,092 | Common Stock |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 83,473 | 2,987,396 (5%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 83,473 | 0 | - | - | Restricted Stock Units | |
| Great Elm Grp Inc | Matthew A. Drapkin | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 82,418 | 693,035 (2%) | 0% | 0 | Common Stock | |
| Helix Energy Soln Grp Inc | Owen E. Kratz | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 81,301 | 7,253,161 (4%) | 0% | - | Common Stock | |
| Helix Energy Soln Grp Inc | Owen E. Kratz | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 81,301 | 81,301 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Owen E. Kratz | Director, PRESIDENT & CEO | Sale or transfer of securities back to the company at price $ 9.68 per share. | 03 Jan 2025 | 81,301 | 7,171,860 (4%) | 0% | 9.7 | 786,994 | Common Stock |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 78,300 | 78,300 | - | - | Stock Option (Right to Buy) | |
| Presidio Property Trust Inc (Class A) | Gary M. Katz | Chief Investment Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. | 03 Jan 2025 | 77,265 | 597,746 | - | 0.7 | 53,313 | Common Stock - Series A |
| AnaptysBio Inc | Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 76,400 | 76,400 | - | - | Stock Option (right to buy) | |
| EyePoint Pharma Inc | Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 75,133 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| Acumen Pharma Inc | Russell Barton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 74,700 | 74,700 | - | - | Employee Stock Option (right to buy) | |
| Darling Ingredients Inc | Randall C. Stuewe | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 73,225 | 767,073 (0%) | 0% | 0 | Common Stock | |
| PENN Entertainment Inc | Felicia R. Hendrix | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 72,651 | 72,651 | - | - | Stock Options (Right to Buy) | |
| Eton Pharma Inc | Sean E. Brynjelsen | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 72,004 | 72,004 | - | - | Restricted Stock Units | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 71,762 | 71,762 | - | - | Restricted Stock Units | |
| Indie Semiconductor Inc (Class A) | Donald McClymont | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 71,625 | 143,250 | - | - | Restricted Stock Units | |
| Indie Semiconductor Inc (Class A) | Donald McClymont | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 71,625 | 96,130 | - | 0 | Class A Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 70,000 | 288,374 (0%) | 0% | 0 | Common Stock | |
| ATI Inc | Timothy J. Harris | Senior VP and CDIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 67,402 | 169,996 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | |
| AnaptysBio Inc | Eric J. Loumeau | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| PENN Entertainment Inc | Todd George | EVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 66,918 | 133,243 (0%) | 0% | 0 | Common Stock | |
| Acumen Pharma Inc | Derek M. Meisner | Chief Legal Officer & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 66,800 | 164,545 | - | 0 | Common Stock | |
| Acumen Pharma Inc | Eric Siemers | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 66,800 | 173,517 | - | 0 | Common Stock | |
| Cleveland-Cliffs Inc | C. Lourenco Goncalves | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 03 Jan 2025 | 66,662 | 2,692,427 (0%) | 0% | 9.5 | 633,289 | Common Shares |
| PENN Entertainment Inc | Christopher Byron Rogers | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 64,579 | 64,579 | - | - | Stock Options (Right to Buy) | |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 63,673 | 426,483 | - | - | Class A Common Stock | |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Jan 2025 | 63,673 | 8,584,927 | - | - | Class C Common Stock | |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 22.02 per share. | 03 Jan 2025 | 63,673 | 362,810 | - | 22.0 | 1,401,844 | Class A Common Stock |
| Intuitive Machines Inc (Class A) | Timothy Crain | SVP and Chief Growth Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 63,673 | 9,699,886 | - | - | Common Units | |
| Helix Energy Soln Grp Inc | Scott A. Sparks | EVP & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 62,767 | 0 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Scott A. Sparks | EVP & COO | Sale or transfer of securities back to the company at price $ 9.52 per share. | 03 Jan 2025 | 62,767 | 112,634 (0%) | 0% | 9.5 | 597,542 | Common Stock |
| Helix Energy Soln Grp Inc | Scott A. Sparks | EVP & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 62,767 | 175,401 (0%) | 0% | - | Common Stock | |
| Nkarta Inc | Nadir Mahmood | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 62,000 | 93,376 | - | 0 | Common Stock | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.74 per share. | 03 Jan 2025 | 59,486 | 3,046,233 (5%) | 0% | 55.7 | 3,315,750 | Common Stock |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 59,000 | 74,000 | - | - | Restricted Stock Units | |
| EyePoint Pharma Inc | Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Nkarta Inc | David R. Shook | See Remarks | 03 Jan 2025 | 59,000 | 199,593 | - | 0 | Common Stock | ||
| Helix Energy Soln Grp Inc | Erik Staffeldt | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 57,426 | 0 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Erik Staffeldt | EVP & CFO | Sale or transfer of securities back to the company at price $ 9.52 per share. | 03 Jan 2025 | 57,426 | 450,999 (0%) | 0% | 9.5 | 546,696 | Common Stock |
| Helix Energy Soln Grp Inc | Erik Staffeldt | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 57,426 | 508,425 (0%) | 0% | - | Common Stock | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 56,250 | 56,250 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Eric Pauwels | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 54,180 | 289,987 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Alexander O. Schuth | COFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 54,180 | 259,470 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 54,180 | 190,835 (0%) | 0% | 0 | Common Stock | |
| Presidio Property Trust Inc (Class A) | Jack Kendrick Heilbron | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. | 03 Jan 2025 | 53,929 | 744,455 | - | 0.7 | 37,211 | Common Stock - Series A |
| Nerdwallet Inc (Class A) | Samuel Yount | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.46 per share. | 03 Jan 2025 | 53,186 | 201,051 | - | 13.5 | 715,884 | Class A Common Stock |
| Nkarta Inc | Alicia J. Hager | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 52,500 | 156,319 | - | 0 | Common Stock | |
| Nkarta Inc | Ralph Brandenberger | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 52,500 | 132,243 | - | 0 | Common Stock | |
| Nkarta Inc | Alyssa Levin | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 52,500 | 108,500 | - | 0 | Common Stock | |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 51,874 | 0 | - | - | Restricted Stock Units | |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 51,874 | 395,015 (1%) | 0% | - | Common Stock | |
| Eton Pharma Inc | Norbert G. Riedel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.78 per share. | 03 Jan 2025 | 50,000 | 137,145 (0%) | 0% | 3.8 | 189,000 | Common Stock |
| Eton Pharma Inc | Norbert G. Riedel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 50,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Kratos Defense & Security Soln Inc | Phillip Carrai | President, STC Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Steven Fendley | President, US Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Acumen Pharma Inc | Russell Barton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 49,800 | 139,031 | - | 0 | Common Stock | |
| Viking Therapeutics Inc | Marianna Mancini | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 42.69 per share. | 03 Jan 2025 | 49,115 | 379,234 (0%) | 0% | 42.7 | 2,096,685 | Common Stock, par value $0.00001 per share |
| PENN Entertainment Inc | Felicia R. Hendrix | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 48,181 | 116,777 (0%) | 0% | 0 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.84 per share. | 03 Jan 2025 | 47,778 | 454,707 | - | 1.8 | 87,873 | Common Stock |
| PTC Therapeutics Inc | Neil Almstead | CHIEF TECHNICAL OPS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 47,500 | 47,500 | - | - | Stock Option (Right to Buy) | |
| Somnigroup Intl Inc | H. Clifford Buster | CEO, North America | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 47,235 | 310,368 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | H. Clifford Buster | CEO, North America | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 47,235 | 0 | - | - | Performance Restricted Stock Units | |
| Great Elm Grp Inc | Eric J. Scheyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 46,704 | 421,719 (1%) | 0% | 0 | Common Stock | |
| Great Elm Grp Inc | Jim Parmelee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 46,704 | 437,714 (1%) | 0% | 0 | Common Stock | |
| ATI Inc | Kimberly A. Fields | President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.63 per share. | 03 Jan 2025 | 46,557 | 281,228 (0%) | 0% | 56.6 | 2,636,523 | Common Stock, par value $0.10 per share |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.05 per share. | 03 Jan 2025 | 46,314 | 197,959 (1%) | 0% | 16.1 | 743,340 | Common Stock |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.69 per share. | 03 Jan 2025 | 45,609 | 169,959 (0%) | 0% | 42.7 | 1,946,993 | Common Stock, par value $0.00001 per share |
| CNX Resources Corp | Nicholas J. DeIuliis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 45,290 | 2,398,706 (1%) | 0% | 0 | Common shares, $0.01 par value per share | |
| Lifeway Foods Inc | Ludmila Smolyansky | Member of 10% owner group | Sale of securities on an exchange or to another person at price $ 23.49 per share. | 03 Jan 2025 | 45,000 | 1,025,549 (6%) | 0% | 23.5 | 1,057,050 | Common Stock, no par value |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 44,533 | 193,901 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Marianna Mancini | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 44,533 | 406,682 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 03 Jan 2025 | 43,135 | 449,140 (0%) | 0% | 4 | 172,540 | Common Shares |
| CNX Resources Corp | Nicholas J. DeIuliis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.12 per share. | 03 Jan 2025 | 42,851 | 2,355,855 (1%) | 0% | 33.1 | 1,419,225 | Common shares, $0.01 par value per share |
| PENN Entertainment Inc | Christopher Byron Rogers | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 42,827 | 87,478 (0%) | 0% | 0 | Common Stock | |
| Helix Energy Soln Grp Inc | Kenneth E. Neikirk | EVP, GEN COUNSEL & SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 42,735 | 0 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Kenneth E. Neikirk | EVP, GEN COUNSEL & SECRETARY | Sale or transfer of securities back to the company at price $ 9.52 per share. | 03 Jan 2025 | 42,735 | 104,459 (0%) | 0% | 9.5 | 406,837 | Common Stock |
| Helix Energy Soln Grp Inc | Kenneth E. Neikirk | EVP, GEN COUNSEL & SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 42,735 | 147,194 (0%) | 0% | - | Common Stock | |
| CNX Resources Corp | Navneet Behl | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 41,516 | 171,584 (0%) | 0% | 0 | Common shares, $0.01 par value per share | |
| EyePoint Pharma Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 41,500 | 41,500 | - | - | Stock Option (Right to Buy) | |
| Great Elm Grp Inc | David Matter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 41,209 | 482,234 (1%) | 0% | 0 | Common Stock | |
| Crown Holdings Inc | Gerard H. Gifford | EVP & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,873 | 155,275 (0%) | 0% | 0 | Common | |
| EyePoint Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | Stuart M. Duty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Kratos Defense & Security Soln Inc | Stacey Rock | President, KTT Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 39,443 | 2,108,618 (7%) | 0% | 3.6 | 142,389 | Common Stock |
| Eton Pharma Inc | James R. Gruber | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 38,621 | 38,621 | - | - | Employee Stock Option (Right to Buy) | |
| Eton Pharma Inc | David C. Krempa | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 38,621 | 38,621 | - | - | Employee Stock Option (Right to Buy) | |
| Photronics Inc | H.K. Park | SVP & GM of FPD Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 38,000 | 140,500 (0%) | 0% | 0 | COMMON STOCK | |
| Photronics Inc | Hsueh-Chun David Wang | SVP/COO IC & US/EU Mnstrm Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 38,000 | 136,250 (0%) | 0% | 0 | COMMON STOCK | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 37,793 | 2,918,795 (5%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 37,793 | 0 | - | - | Restricted Stock Units | |
| CNX Resources Corp | Alan K. Shepard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 37,742 | 216,598 (0%) | 0% | 0 | Common shares, $0.01 par value per share | |
| Hub Grp Inc (Class A) | Phillip D. Yeager | Director, President, CEO & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 37,639 | 203,095 (0%) | 0% | 0 | Class A Common Stock | |
| ATI Inc | Donald P. Newman | EVP and CFO | 03 Jan 2025 | 37,245 | 249,111 (0%) | 0% | 56.6 | 2,109,184 | Common Stock, par value $0.10 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 37,200 | 37,200 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Marianna Mancini | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 37,200 | 37,200 | - | - | Stock Option (Right to Buy) | |
| Hurco Companies Inc | Gregory Volovic | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 37,009 | 127,331 (1%) | 0% | 0 | Common Stock | |
| Great Elm Grp Inc | Matthew A. Drapkin | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 35,714 | 610,617 (2%) | 0% | 0 | Common Stock | |
| Great Elm Grp Inc | Matthew A. Drapkin | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 35,714 | 728,749 (2%) | 0% | 0 | Common Stock | |
| Great Elm Grp Inc | James H. Hugar | Director | 03 Jan 2025 | 35,714 | 343,067 (1%) | 0% | 0 | Common Stock | ||
| Great Elm Grp Inc | Eric J. Scheyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 35,714 | 375,015 (1%) | 0% | 0 | Common Stock | |
| Great Elm Grp Inc | Jim Parmelee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 35,714 | 391,227 (1%) | 0% | 0 | Common Stock | |
| Great Elm Grp Inc | David Matter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 35,714 | 441,025 (1%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Christine Utter | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Itron Inc | Thomas L. Deitrich | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,787 | 0 | - | - | Stock Option (Right to Buy) | |
| Itron Inc | Thomas L. Deitrich | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.13 per share. | 03 Jan 2025 | 34,787 | 239,180 (0%) | 0% | 35.1 | 1,222,067 | Common Stock |
| Itron Inc | Thomas L. Deitrich | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 110.20 per share. | 03 Jan 2025 | 34,787 | 204,393 (0%) | 0% | 110.2 | 3,833,458 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 438,036 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 104,032 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 34,100 | 34,100 | - | - | Restricted Stock Unit | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.74 per share. | 03 Jan 2025 | 32,847 | 2,954,549 (5%) | 0% | 55.7 | 1,830,892 | Common Stock |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.72 per share. | 03 Jan 2025 | 32,609 | 363,798 (1%) | 0% | 31.7 | 1,034,357 | Common Stock |
| Serve Robotics Inc | Ali Kashani | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.90 per share. | 03 Jan 2025 | 32,500 | 3,235,990 | - | 20.9 | 679,351 | Common Stock |
| Xeris Biopharma Holdings Inc | Steven M. Pieper | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 32,059 | 1,409,761 (5%) | 0% | 3.6 | 115,733 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 32,039 | 1,352,794 (4%) | 0% | 3.6 | 115,661 | Common Stock |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 31,153 | 207,909 | - | - | Restricted Stock Unit | |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 31,152 | 239,061 | - | - | Restricted Stock Unit | |
| Helix Energy Soln Grp Inc | Scott A. Sparks | EVP & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 31,052 | 143,686 (0%) | 0% | - | Common Stock | |
| Helix Energy Soln Grp Inc | Scott A. Sparks | EVP & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 31,052 | 31,053 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Scott A. Sparks | EVP & COO | Sale or transfer of securities back to the company at price $ 9.68 per share. | 03 Jan 2025 | 31,052 | 112,634 (0%) | 0% | 9.7 | 300,583 | Common Stock |
| ASA Gold and Precious Metals Ltd | Alexander Merk | COO | Purchase of securities on an exchange or from another person at price $ 20.98 per share. | 03 Jan 2025 | 30,825 | 180,723 (0%) | 0% | 21.0 | 646,684 | ASA Gold & Precious Metals Ltd |
| Presidio Property Trust Inc (Class A) | Edwin H. Bentzen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. | 03 Jan 2025 | 30,310 | 213,068 | - | 0.7 | 20,914 | Common Stock - Series A |
| CNX Resources Corp | Hayley F. Scott | Chief Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 30,194 | 124,510 (0%) | 0% | 0 | Common shares, $0.01 par value per share | |
| CNX Resources Corp | Ravi Srivastava | President New Technologies | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 30,194 | 151,496 (0%) | 0% | 0 | Common shares, $0.01 par value per share | |
| CNX Resources Corp | Timothy Scott Bedard | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 30,194 | 95,455 (0%) | 0% | 0 | Common shares, $0.01 par value per share | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 60,000 | - | - | Restricted Stock Units | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 68,027 (0%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 1,215,202 (1%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 120,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 90,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 60,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 1,269,787 (1%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 1,251,592 (1%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Eric M. Demarco | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 1,233,397 (1%) | 0% | 0 | Common Stock | |
| ATI Inc | Timothy J. Harris | Senior VP and CDIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.63 per share. | 03 Jan 2025 | 29,516 | 140,480 (0%) | 0% | 56.6 | 1,671,491 | Common Stock, par value $0.10 per share |
| Helix Energy Soln Grp Inc | Erik Staffeldt | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,359 | 480,358 (0%) | 0% | - | Common Stock | |
| Helix Energy Soln Grp Inc | Erik Staffeldt | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,359 | 29,359 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Erik Staffeldt | EVP & CFO | Sale or transfer of securities back to the company at price $ 9.68 per share. | 03 Jan 2025 | 29,359 | 450,999 (0%) | 0% | 9.7 | 284,195 | Common Stock |
| Somnigroup Intl Inc | Bhaskar Rao | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,286 | 0 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Bhaskar Rao | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,286 | 410,454 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Steven H. Rusing | EVP, President, U.S. Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,286 | 278,431 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Steven H. Rusing | EVP, President, U.S. Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,286 | 0 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Scott J. Vollet | EVP, Global Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,286 | 0 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Scott J. Vollet | EVP, Global Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 29,286 | 450,128 (0%) | 0% | 0 | Common Stock | |
| Hub Grp Inc (Class A) | David P. Yeager | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 29,216 | 359,699 (1%) | 0% | 0 | Class A Common Stock | |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 28,816 | 343,141 (1%) | 0% | 0 | Common Stock | |
| LiqTech Intl Inc | Fei Chen | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 03 Jan 2025 | 28,394 | 310,279 (1%) | 0% | 1.9 | 53,097 | Common Stock |
| Hurco Companies Inc | Michael Doar | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 28,198 | 217,596 (3%) | 0% | 0 | Common Stock | |
| Spok Holdings Inc | Michael W. Wallace | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.05 per share. | 03 Jan 2025 | 28,195 | 65,660 (0%) | 0% | 16.1 | 452,530 | Common Stock |
| Range Cap Acq Corp | Timothy Rotolo | Director, CEO and CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2025 | 28,125 | 4,036,458 | - | - | Ordinary Shares | |
| Chewy Inc (Class A) | Sumit Singh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.03 per share. | 03 Jan 2025 | 28,074 | 707,126 (1%) | 0% | 36.0 | 1,011,562 | Class A Common Stock |
| Everspin Tech Inc | Sanjeev Aggarwal | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 6.29 per share. | 03 Jan 2025 | 28,058 | 412,157 (2%) | 0% | 6.3 | 176,485 | Common Stock |
| Indie Semiconductor Inc (Class A) | Donald McClymont | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.69 per share. | 03 Jan 2025 | 27,966 | 65,932 | - | 4.7 | 131,161 | Class A Common Stock |
| Freshpet Inc | William B. Cyr | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 27,716 | 66,067 (0%) | 0% | 0 | Common Stock | |
| Eton Pharma Inc | Norbert G. Riedel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 27,400 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Eton Pharma Inc | Norbert G. Riedel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.58 per share. | 03 Jan 2025 | 27,400 | 87,145 (0%) | 0% | 3.6 | 98,092 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 26,807 | 941,115 (1%) | 0% | 12.2 | 326,509 | Common Stock |
| AnaptysBio Inc | Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 26,800 | 26,800 | - | - | Restricted Stock Unit | |
| Avnet Inc | Philip R. Gallagher | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.28 per share. | 03 Jan 2025 | 26,341 | 205,471 (0%) | 0% | 52.3 | 1,377,107 | Common Stock |
| Eton Pharma Inc | James R. Gruber | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 25,876 | 25,876 | - | - | Restricted Stock Units | |
| Eton Pharma Inc | David C. Krempa | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 25,876 | 25,876 | - | - | Restricted Stock Units | |
| Eton Pharma Inc | Charles J. Casamento | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eton Pharma Inc | Norbert G. Riedel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eton Pharma Inc | Norbert G. Riedel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.47 per share. | 03 Jan 2025 | 25,000 | 162,145 (0%) | 0% | 3.5 | 86,750 | Common Stock |
| Eton Pharma Inc | Norbert G. Riedel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 25,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Eton Pharma Inc | Paul Victor Maier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eton Pharma Inc | Jennifer McKie Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Coinbase Global Inc (Class A) | Brian Armstrong | Director, Chairman and CEO, Ten Percent Owner | 03 Jan 2025 | 25,000 | 25,526 | - | 0 | Class A Common Stock | ||
| Coinbase Global Inc (Class A) | Brian Armstrong | Director, Chairman and CEO, Ten Percent Owner | 03 Jan 2025 | 25,000 | 24,206,225 | - | - | Class B Common Stock | ||
| Finnovate Acq Corp (Class A) | Calvin Kung | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 03 Jan 2025 | 25,000 | 25,000 | - | 0 | Class A Ordinary Shares, par value $0.0001 per share | |
| Crown Holdings Inc | Kevin C. Clothier | Senior Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 24,530 | 68,291 (0%) | 0% | 0 | Common | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 24,501 | 1,577,452 (5%) | 0% | 3.6 | 88,449 | Common Stock |
| Cineverse Corp (Class A) | Peter C. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 24,433 | 127,948 (0%) | 0% | 0 | Class A Common Stock | |
| Cineverse Corp (Class A) | Patrick O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 24,433 | 128,493 (0%) | 0% | 0 | Class A Common Stock | |
| Cineverse Corp (Class A) | Mary Ann Halford | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 24,433 | 265,548 (0%) | 0% | 0 | Class A Common Stock | |
| Somnigroup Intl Inc | H. Clifford Buster | CEO, North America | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 24,050 | 316,487 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | H. Clifford Buster | CEO, North America | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 24,050 | 48,097 | - | - | Performance Restricted Stock Units | |
| AnaptysBio Inc | Eric J. Loumeau | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 23,550 | 23,550 | - | - | Restricted Stock Unit | |
| Hurco Companies Inc | Sonja K. Mcclelland | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 23,497 | 102,290 (1%) | 0% | 0 | Common Stock | |
| Koppers Holdings Inc | James A. Sullivan | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 23,052 | 134,243 (0%) | 0% | 0 | Common Stock | |
| Meta | Mark Zuckerberg | Director, COB and CEO, Ten Percent Owner | 03 Jan 2025 | 22,946 | 193,642,612 | - | - | Class B Common Stock | ||
| Meta | Mark Zuckerberg | Director, COB and CEO, Ten Percent Owner | 03 Jan 2025 | 22,946 | 22,946 (0%) | 0% | 0 | Class A Common Stock | ||
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 22,500 | 76,771 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | H. Clifford Buster | CEO, North America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 22,426 | 22,426 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 22,148 | 22,148 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Eric Pauwels | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 22,000 | 90,540 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | H. Clifford Buster | CEO, North America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.74 per share. | 03 Jan 2025 | 21,919 | 288,449 (0%) | 0% | 55.7 | 1,221,765 | Common Stock |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 21,667 | 215,568 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Marianna Mancini | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 21,667 | 428,349 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Helix Energy Soln Grp Inc | Kenneth E. Neikirk | EVP, GEN COUNSEL & SECRETARY | Sale or transfer of securities back to the company at price $ 9.68 per share. | 03 Jan 2025 | 21,454 | 104,459 (0%) | 0% | 9.7 | 207,675 | Common Stock |
| Helix Energy Soln Grp Inc | Kenneth E. Neikirk | EVP, GEN COUNSEL & SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 21,454 | 21,455 | - | - | Restricted Stock Units | |
| Helix Energy Soln Grp Inc | Kenneth E. Neikirk | EVP, GEN COUNSEL & SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 21,454 | 125,913 (0%) | 0% | - | Common Stock | |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.05 per share. | 03 Jan 2025 | 21,396 | 176,563 (0%) | 0% | 16.1 | 343,406 | Common Stock |
| ATI Inc | Tina Killough Busch | SVP, CHRO | 03 Jan 2025 | 21,360 | 44,300 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | ||
| Hub Grp Inc (Class A) | Phillip D. Yeager | Director, President, CEO & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 21,192 | 165,456 (0%) | 0% | 0 | Class A Common Stock | |
| Crown Holdings Inc | Timothy J. Donahue | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Jan 2025 | 21,123 | 512,120 (0%) | 0% | 0 | Common | |
| Presidio Property Trust Inc (Class A) | Steven Hightower | Director, President, Netreit Advisors | Grant, award, or other acquisition of securities at price $ 0.69 per share. | 03 Jan 2025 | 21,104 | 96,869 | - | 0.7 | 14,562 | Common Stock - Series A |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 78,814 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 39,206 | - | - | Restricted Stock Units | |
| CNX Resources Corp | Alan K. Shepard | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.12 per share. | 03 Jan 2025 | 20,491 | 196,107 (0%) | 0% | 33.1 | 678,662 | Common shares, $0.01 par value per share |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,936 | 48,662 | - | - | Restricted Stock Units | |
| Healthcare Services Grp Inc | Vikas Singh | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,898 | 19,898 | - | - | Restricted Stock Units | |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,862 | 51,874 | - | - | Restricted Stock Units | |
| PubMatic Inc Ordinary Shares | Steven Pantelick | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.15 per share. | 03 Jan 2025 | 19,779 | 22,506 | - | 15.1 | 299,579 | Class A Common Stock |
| PENN Entertainment Inc | David A. Handler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,491 | 312,941 (0%) | 0% | 0 | Common Stock | |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 19,268 | 0 | - | - | Restricted Stock Unit | |
| Hub Grp Inc (Class A) | David P. Yeager | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,246 | 378,945 (1%) | 0% | 0 | Class A Common Stock | |
| Healthcare Services Grp Inc | Vikas Singh | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,233 | 19,233 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 03 Jan 2025 | 19,000 | 2,366,570 (3%) | 0% | 43.3 | 823,021 | Common Stock, par value $0.00001 per share |
| PTC Therapeutics Inc | Neil Almstead | CHIEF TECHNICAL OPS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,000 | 106,048 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | David Montgomery | EVP Global Business Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 18,897 | 860,842 (1%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | David Montgomery | EVP Global Business Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 18,897 | 0 | - | - | Performance Restricted Stock Units | |
| Indie Semiconductor Inc (Class A) | Michael Wittmann | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 18,750 | 37,500 | - | - | Restricted Stock Units | |
| Indie Semiconductor Inc (Class A) | Michael Wittmann | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 18,750 | 45,927 | - | 0 | Class A Common Stock | |
| ATI Inc | Kimberly A. Fields | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,713 | 219,346 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | |
| Spok Holdings Inc | Michael W. Wallace | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,692 | 126,374 | - | - | Restricted Stock Unit | |
| Spok Holdings Inc | Michael W. Wallace | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,691 | 145,065 | - | - | Restricted Stock Unit | |
| Crown Holdings Inc | Djalma Novaes | President - Americas Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,527 | 121,737 (0%) | 0% | 0 | Common | |
| ON24 Inc | Steven Vattuone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 03 Jan 2025 | 18,376 | 562,762 | - | 1.2 | 22,602 | Common Stock |
| ON24 Inc | Steven Vattuone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 03 Jan 2025 | 18,376 | 544,386 | - | 6.6 | 121,039 | Common Stock |
| ON24 Inc | Steven Vattuone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 18,376 | 6,624 | - | - | Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,293 | 18,293 | - | - | Restricted Stock Units | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,000 | 110,389 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 442,853 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 35,700 | - | - | Restricted Stock Unit | |
| ATI Inc | Robert S. Wetherbee | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 17,822 | 454,265 (0%) | 0% | 0 | Common Stock, par value $0.10 per share | |
| PTC Therapeutics Inc | Michael Schmertzler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| TD Synnex Corp | Richard T. Hume | Director | Sale of securities on an exchange or to another person at price $ 117.66 per share. | 03 Jan 2025 | 17,589 | 112,282 (0%) | 0% | 117.7 | 2,069,522 | Common Stock |
| Kratos Defense & Security Soln Inc | Marie Mendoza | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 17,500 | 17,500 | - | - | Restricted Stock Units | |
| Rubrik Inc (Class A) | Brian McCarthy | Chief Revenue Officer | Sale of securities on an exchange or to another person at price $ 67.03 per share. | 03 Jan 2025 | 17,245 | 325,560 | - | 67.0 | 1,155,932 | Class A Common Stock |
| Koppers Holdings Inc | James A. Sullivan | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,146 | 151,389 (0%) | 0% | - | Common Stock | |
| Koppers Holdings Inc | James A. Sullivan | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,146 | 0 | - | - | Restricted Stock Units | |
| CNX Resources Corp | Navneet Behl | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.12 per share. | 03 Jan 2025 | 16,967 | 154,617 (0%) | 0% | 33.1 | 561,947 | Common shares, $0.01 par value per share |
| Kratos Defense & Security Soln Inc | Maria Cervantes de Burgreen | VP & Corp. Controller | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 03 Jan 2025 | 16,528 | 54,121 (0%) | 0% | 30 | 495,840 | Common Stock |
| Galecto Inc | Hans T. Schambye | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 16,400 | 16,400 | - | - | Stock Option (right to buy) | |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 16,280 | 16,280 | - | - | Restricted Stock Units | |
| Somnigroup Intl Inc | Hansbart Wijnand | EVP, INTERNATIONAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 16,059 | 50,469 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Hansbart Wijnand | EVP, INTERNATIONAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 16,059 | 0 | - | - | Performance Restricted Stock Units | |
| BlackBerry Ltd | Mattias Eriksson | President of IoT | 03 Jan 2025 | 16,008 | 258,481 (0%) | 0% | - | Common Shares | ||
| BlackBerry Ltd | Mattias Eriksson | President of IoT | 03 Jan 2025 | 16,008 | 0 | - | - | Restricted Share Units | ||
| LQR House Inc | Sean Dollinger | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,625 | 92,868 | - | 0 | Common Stock | |
| LQR House Inc | Sean Dollinger | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,625 | 9,375 | - | - | Restricted Stock Units | |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 14,715 | - | - | Restricted Stock Units | |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 73,374 (0%) | 0% | 0 | Common Stock | |
| Crown Holdings Inc | Adam J. Dickstein | SVP, Gen Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 15,221 | 62,778 (0%) | 0% | 0 | Common | |
| Rocky Mountain Chocolate Factory Inc | Steven L. Craig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 15,209 | 283,419 (4%) | 0% | 0 | Common Stock | |
| Citizens Inc (Class A) | Harvey J.L. Waite | Chief Actuary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,070 | 68,461 (0%) | 0% | - | Citizens, Inc. Class A Common Stock | |
| Citizens Inc (Class A) | Harvey J.L. Waite | Chief Actuary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,070 | 30,141 | - | - | Restricted Stock Units | |
| Cloudflare Inc (Class A) | Thomas Josef Seifert | Chief Financial Officer | 03 Jan 2025 | 15,000 | 267,869 (0%) | 0% | - | Class A Common Stock | ||
| Cloudflare Inc (Class A) | Thomas Josef Seifert | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 300,341 | - | - | Employee Stock Option (right to buy) | |
| Cloudflare Inc (Class A) | Thomas Josef Seifert | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 23,925 | - | - | Class B Common Stock | |
| Cloudflare Inc (Class A) | Thomas Josef Seifert | Chief Financial Officer | 03 Jan 2025 | 15,000 | 8,925 | - | - | Class B Common Stock | ||
| Crinetics Pharma Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jan 2025 | 15,000 | 44,248 (0%) | 0% | 16.9 | 253,350 | Common Stock |
| Crinetics Pharma Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 52.09 per share. | 03 Jan 2025 | 15,000 | 29,248 (0%) | 0% | 52.1 | 781,350 | Common Stock |
| Crinetics Pharma Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 124,042 | - | - | Stock option (Right to Buy) | |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 63,356 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 30,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 60,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 45,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 30,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 0 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 306,482 (0%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 298,959 (0%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 291,436 (0%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 276,688 (0%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 283,913 (0%) | 0% | 0 | Common Stock | |
| Kratos Defense & Security Soln Inc | Thomas E. Mills | President, C5ISR Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | Yonah Adelman | President, ME Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Kratos Defense & Security Soln Inc | David Carter | President, DRSS Division | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Lifeway Foods Inc | Ludmila Smolyansky | Member of 10% owner group | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 03 Jan 2025 | 15,000 | 1,040,549 (6%) | 0% | 24.1 | 361,800 | Common Stock, no par value |
| Finnovate Acq Corp (Class A) | Wang Chiu Wong | Director, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 15,000 | - | 0 | Class A Ordinary Share, par value $0.0001 per share | |
| Somnigroup Intl Inc | Bhaskar Rao | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,911 | 29,820 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Bhaskar Rao | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,911 | 414,360 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Steven H. Rusing | EVP, President, U.S. Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,911 | 282,165 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Steven H. Rusing | EVP, President, U.S. Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,911 | 29,820 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Scott J. Vollet | EVP, Global Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,911 | 29,820 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Scott J. Vollet | EVP, Global Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,911 | 454,034 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.74 per share. | 03 Jan 2025 | 14,872 | 2,903,923 (5%) | 0% | 55.7 | 828,965 | Common Stock |
| Darling Ingredients Inc | Randall C. Stuewe | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.69 per share. | 03 Jan 2025 | 14,826 | 752,247 (0%) | 0% | 34.7 | 514,314 | Common Stock |
| Cleveland-Cliffs Inc | Keith A. Koci | EVP & President, CC Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 03 Jan 2025 | 14,704 | 431,552 (0%) | 0% | 9.5 | 139,688 | Common Shares |
| Cleveland-Cliffs Inc | Celso L. Goncalves | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 03 Jan 2025 | 14,704 | 299,657 (0%) | 0% | 9.5 | 139,688 | Common Shares |
| Cleveland-Cliffs Inc | Clifford Smith | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 03 Jan 2025 | 14,269 | 555,840 (0%) | 0% | 9.5 | 135,556 | Common Shares |
| Toast Inc (Class A) | Elena Gomez | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.11 per share. | 03 Jan 2025 | 14,143 | 158,637 | - | 37.1 | 524,804 | Class A Common Stock |
| Citizens Inc (Class A) | Cynthia H. Davis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,035 | 45,541 (0%) | 0% | - | Citizens, Inc. Class A Common Stock | |
| Citizens Inc (Class A) | Cynthia H. Davis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,035 | 0 | - | - | Restricted Stock Units | |
| Citizens Inc (Class A) | Mary Taylor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,035 | 0 | - | - | Restricted Stock Units | |
| Citizens Inc (Class A) | Mary Taylor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 14,035 | 47,655 (0%) | 0% | - | Citizens, Inc. Class A Common Stock | |
| PTC Therapeutics Inc | Christine Utter | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 14,000 | 67,274 (0%) | 0% | 0 | Common Stock | |
| Somnigroup Intl Inc | Bhaskar Rao | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 13,904 | 13,904 | - | - | Restricted Stock Units | |
| Somnigroup Intl Inc | Steven H. Rusing | EVP, President, U.S. Sales | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 13,904 | 13,904 | - | - | Restricted Stock Units | |
| Somnigroup Intl Inc | Scott J. Vollet | EVP, Global Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 13,904 | 13,904 | - | - | Restricted Stock Units | |
| CNX Resources Corp | Ravi Srivastava | President New Technologies | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.12 per share. | 03 Jan 2025 | 13,899 | 137,597 (0%) | 0% | 33.1 | 460,335 | Common shares, $0.01 par value per share |
| Freshpet Inc | Scott Morris | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 13,858 | 136,238 (0%) | 0% | 0 | Common Stock | |
| Koppers Holdings Inc | James A. Sullivan | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.72 per share. | 03 Jan 2025 | 13,786 | 138,126 (0%) | 0% | 31.7 | 437,292 | Common Stock |
| Dollar Tree | Michael C. Creedon | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 13,706 | 13,706 | - | - | Stock Option (right to buy) |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.